In the past 20 years, the survival of GIST patients has been remarkably prolonged by the introduction of tyrosine kinase inhibitors (TKIs) targeting gene mutations, mostly KIT or PDGFRA. The gene discussed is PDGFRA; the disease is gastrointestinal stromal tumor.